Manchester United FC extend Canon Medical Systems partnership
Manchester United Football Club have announced a three-year extension of their long-standing partnership with Canon Medical Systems.
The partnership with the Japanese medical equipment company has been in place since 2013 and covers the men’s, women’s, and academy divisions of the club. The extension will see Canon Medical equipment remain integrated into the Red Devils’ daily medical operations at their training facilities at Carrington and provide cardiac, musculoskeletal, and general sports medicine imaging, while also bringing upgrades to the existing MRI, ultrasound, and healthcare IT setup.
New research-focused initiatives are also part of the new agreement in the areas of musculoskeletal imaging, injury detection and monitoring, and sex-based differences in injury patterns. This work with elite athletes will be carried out with the aim of wider real-world application.
Dr Gary O’Driscoll, Head of Sports Medicine at Manchester United FC, commented:
“We are delighted to extend our partnership with Canon Medical Systems, a collaboration that has been fundamental to advancing the health and performance of our players over the past 12 years. Their cutting-edge imaging technology and shared commitment to research have enabled us to enhance injury prevention, diagnosis, and rehabilitation across our men’s, women’s, and academy teams. This renewed partnership reinforces our dedication to providing the highest standard of care and innovation to support our athletes both on and off the pitch.”
René Degros, Vice President of Canon Medical Systems Europe, added:
“This extension of our partnership with Manchester United reflects more than a decade of close collaboration and shared commitment to innovation in sports medicine. From cardiac screening to injury rehabilitation, our imaging systems continue to play a vital role in supporting player health and performance. We are proud to work alongside one of the world’s largest football clubs as we further expand our research and clinical focus over the next three years.”
